ReAlta Life Sciences is a renowned brand dedicated to addressing life-threatening diseases by harnessing the power of the immune system. With a focus on rare diseases, ReAlta has developed a groundbreaking class of drugs that possess unique dual-targeting therapeutic capabilities, effectively rebalancing complement and inflammatory processes. Their EPICC platform presents an innovative opportunity to modify disease progression by moderating the most robust components of both humoral (complement system) and cellular (neutrophils) responses.

ReAlta's first target is the complement pathway, with EPICC molecules that rapidly and dose-dependently inhibit C1 and MBL - the earliest initiators of the classical and lectin complement pathways - through transformational changes of serine proteases. Additionally, the EPICC platform acts as a powerful inhibitor of innate, neutrophil-mediated inflammatory processes. ReAlta Life Sciences' research and development initiatives primarily focus on rare diseases in three major therapeutic areas: Hypoxic Ischemic Encephalopathy (HIE) in neurology, Acute Lung Injury (ALI) in pulmonary, and Platelet Refractoriness (PTR) in hematology.

These conditions encompass various debilitating effects caused by oxygen deprivation, inflammatory processes, and increased risk of life-threatening hemorrhage in patients. With an impressive number of patents and peer-reviewed publications, ReAlta Life Sciences is committed to providing innovative solutions to the medical community. Upheld by their core values of patient well-being, integrity, creative strides, and unity, ReAlta embraces continuous advancement in their quest to save lives.

Visit their website for the latest news, events, and resources